Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
Strides Pharma gets FDA greenlight to market HIV treatment – Pharmaceutical Technology
The three tablets, Efavirenz, Emtricitabine and Tenofovir Disproxil Fumurate, known collectively as EET, have all seen approval as generic alternatives to Gilead’s Atripla. Credit: Shutterstock
October 4, 2023